Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 98 | 2024 | 1762 | 13.480 |
Why?
|
Cystectomy | 16 | 2023 | 104 | 5.040 |
Why?
|
Patient Readmission | 18 | 2023 | 346 | 4.510 |
Why?
|
Urinary Bladder Neoplasms | 20 | 2023 | 392 | 4.310 |
Why?
|
Urology | 15 | 2024 | 117 | 3.630 |
Why?
|
Delivery of Health Care | 21 | 2023 | 432 | 3.580 |
Why?
|
Prostate-Specific Antigen | 20 | 2024 | 357 | 3.440 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 7 | 2024 | 119 | 3.360 |
Why?
|
Prostatectomy | 21 | 2023 | 476 | 3.300 |
Why?
|
Androgen Antagonists | 12 | 2024 | 154 | 3.250 |
Why?
|
Male | 148 | 2024 | 41840 | 2.430 |
Why?
|
Aged | 95 | 2024 | 18834 | 2.030 |
Why?
|
Humans | 184 | 2024 | 88286 | 2.020 |
Why?
|
Clinical Trials as Topic | 4 | 2024 | 1141 | 1.890 |
Why?
|
United States | 66 | 2024 | 6857 | 1.840 |
Why?
|
Androstenes | 6 | 2024 | 43 | 1.840 |
Why?
|
Quality of Health Care | 13 | 2019 | 383 | 1.800 |
Why?
|
Phenylthiohydantoin | 5 | 2024 | 48 | 1.780 |
Why?
|
Survivors | 9 | 2016 | 234 | 1.690 |
Why?
|
Urologic Neoplasms | 5 | 2024 | 81 | 1.660 |
Why?
|
Medical Oncology | 4 | 2024 | 375 | 1.640 |
Why?
|
Postoperative Complications | 14 | 2020 | 2272 | 1.640 |
Why?
|
Quality of Life | 20 | 2024 | 1646 | 1.590 |
Why?
|
Cancer Survivors | 5 | 2022 | 92 | 1.580 |
Why?
|
Prostatic Hyperplasia | 3 | 2019 | 91 | 1.570 |
Why?
|
Veterans | 4 | 2021 | 83 | 1.560 |
Why?
|
Medicare | 27 | 2023 | 420 | 1.540 |
Why?
|
Veterans Health | 7 | 2020 | 16 | 1.540 |
Why?
|
Prostate | 9 | 2023 | 391 | 1.530 |
Why?
|
Survivorship | 5 | 2021 | 19 | 1.520 |
Why?
|
Telemedicine | 7 | 2024 | 178 | 1.490 |
Why?
|
Practice Patterns, Physicians' | 17 | 2024 | 597 | 1.450 |
Why?
|
United States Department of Veterans Affairs | 11 | 2021 | 31 | 1.410 |
Why?
|
Self-Management | 3 | 2019 | 38 | 1.380 |
Why?
|
Patient Discharge | 8 | 2023 | 316 | 1.340 |
Why?
|
Primary Health Care | 5 | 2020 | 350 | 1.290 |
Why?
|
Research Design | 7 | 2021 | 593 | 1.260 |
Why?
|
Ketoconazole | 2 | 2024 | 26 | 1.190 |
Why?
|
Aged, 80 and over | 37 | 2024 | 6687 | 1.170 |
Why?
|
Urinary Catheterization | 3 | 2024 | 36 | 1.090 |
Why?
|
Sexual Partners | 7 | 2022 | 98 | 1.040 |
Why?
|
Physicians, Primary Care | 3 | 2024 | 105 | 1.030 |
Why?
|
Neoplasms | 7 | 2023 | 2996 | 1.000 |
Why?
|
Osteoporosis | 2 | 2017 | 122 | 1.000 |
Why?
|
Retrospective Studies | 43 | 2024 | 8836 | 0.990 |
Why?
|
Surgical Procedures, Operative | 5 | 2024 | 200 | 0.990 |
Why?
|
Urologists | 7 | 2024 | 29 | 0.980 |
Why?
|
Robotics | 4 | 2012 | 268 | 0.970 |
Why?
|
Treatment Outcome | 25 | 2024 | 8125 | 0.970 |
Why?
|
Middle Aged | 48 | 2024 | 25571 | 0.940 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2024 | 156 | 0.930 |
Why?
|
Patient-Centered Care | 4 | 2021 | 207 | 0.930 |
Why?
|
Medicare Part D | 3 | 2021 | 10 | 0.850 |
Why?
|
Bibliometrics | 2 | 2019 | 37 | 0.840 |
Why?
|
Watchful Waiting | 6 | 2024 | 61 | 0.840 |
Why?
|
Patient Care | 1 | 2023 | 101 | 0.830 |
Why?
|
Arthroplasty, Replacement, Knee | 4 | 2019 | 115 | 0.820 |
Why?
|
Patient Education as Topic | 4 | 2019 | 355 | 0.810 |
Why?
|
Aftercare | 4 | 2023 | 87 | 0.790 |
Why?
|
Names | 1 | 2021 | 10 | 0.780 |
Why?
|
Life Expectancy | 6 | 2021 | 86 | 0.770 |
Why?
|
Surgeons | 3 | 2024 | 243 | 0.770 |
Why?
|
Nitriles | 7 | 2024 | 160 | 0.740 |
Why?
|
Drug Prescriptions | 3 | 2021 | 144 | 0.740 |
Why?
|
Neoplasm Staging | 12 | 2019 | 1974 | 0.730 |
Why?
|
Bone Neoplasms | 2 | 2023 | 331 | 0.720 |
Why?
|
Reimbursement, Incentive | 1 | 2020 | 37 | 0.720 |
Why?
|
Physicians | 3 | 2023 | 684 | 0.710 |
Why?
|
Radiotherapy, Intensity-Modulated | 9 | 2017 | 176 | 0.710 |
Why?
|
Transurethral Resection of Prostate | 1 | 2019 | 9 | 0.710 |
Why?
|
Sexual Dysfunction, Physiological | 4 | 2022 | 69 | 0.700 |
Why?
|
Urinary Diversion | 2 | 2017 | 42 | 0.690 |
Why?
|
Information Dissemination | 2 | 2017 | 111 | 0.680 |
Why?
|
Health Expenditures | 3 | 2020 | 90 | 0.670 |
Why?
|
Electronic Health Records | 3 | 2021 | 340 | 0.670 |
Why?
|
Orchiectomy | 2 | 2018 | 72 | 0.670 |
Why?
|
SEER Program | 16 | 2022 | 196 | 0.670 |
Why?
|
Castration | 1 | 2018 | 41 | 0.660 |
Why?
|
Accountable Care Organizations | 5 | 2019 | 13 | 0.660 |
Why?
|
Logistic Models | 10 | 2021 | 1202 | 0.650 |
Why?
|
Arthroplasty, Replacement, Hip | 2 | 2019 | 101 | 0.650 |
Why?
|
Publishing | 1 | 2019 | 91 | 0.650 |
Why?
|
Models, Theoretical | 2 | 2019 | 489 | 0.650 |
Why?
|
Erectile Dysfunction | 7 | 2023 | 75 | 0.630 |
Why?
|
Spouses | 2 | 2017 | 32 | 0.630 |
Why?
|
Length of Stay | 6 | 2020 | 722 | 0.620 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 45 | 0.610 |
Why?
|
Urinary Bladder | 2 | 2017 | 246 | 0.610 |
Why?
|
Health Plan Implementation | 1 | 2018 | 56 | 0.600 |
Why?
|
Practice Guidelines as Topic | 5 | 2019 | 1034 | 0.600 |
Why?
|
Time Factors | 14 | 2024 | 5299 | 0.600 |
Why?
|
Machine Learning | 1 | 2020 | 241 | 0.600 |
Why?
|
Insurance Coverage | 2 | 2020 | 117 | 0.590 |
Why?
|
Female | 43 | 2024 | 45560 | 0.590 |
Why?
|
Delivery of Health Care, Integrated | 4 | 2019 | 59 | 0.570 |
Why?
|
Odds Ratio | 8 | 2019 | 684 | 0.570 |
Why?
|
Interviews as Topic | 3 | 2019 | 333 | 0.570 |
Why?
|
Health Education | 1 | 2017 | 101 | 0.570 |
Why?
|
Kidney Neoplasms | 4 | 2010 | 630 | 0.560 |
Why?
|
Survival Rate | 11 | 2020 | 1881 | 0.560 |
Why?
|
Fractures, Bone | 1 | 2017 | 123 | 0.550 |
Why?
|
Replantation | 1 | 2016 | 36 | 0.550 |
Why?
|
Hospital Costs | 1 | 2017 | 107 | 0.550 |
Why?
|
Prognosis | 12 | 2024 | 3740 | 0.540 |
Why?
|
Ureteral Obstruction | 1 | 2016 | 67 | 0.530 |
Why?
|
Self Care | 1 | 2017 | 164 | 0.530 |
Why?
|
Consumer Health Information | 1 | 2015 | 14 | 0.530 |
Why?
|
Ureter | 1 | 2016 | 93 | 0.520 |
Why?
|
Unnecessary Procedures | 6 | 2020 | 51 | 0.490 |
Why?
|
Rural Population | 3 | 2015 | 143 | 0.490 |
Why?
|
Cohort Studies | 15 | 2021 | 2827 | 0.490 |
Why?
|
Benzamides | 5 | 2024 | 239 | 0.490 |
Why?
|
Bone Density Conservation Agents | 1 | 2014 | 45 | 0.480 |
Why?
|
Health Care Costs | 7 | 2019 | 233 | 0.480 |
Why?
|
Cost of Illness | 2 | 2017 | 148 | 0.480 |
Why?
|
Exercise Therapy | 1 | 2014 | 80 | 0.480 |
Why?
|
Biomedical Research | 2 | 2018 | 386 | 0.460 |
Why?
|
Qualitative Research | 3 | 2024 | 282 | 0.460 |
Why?
|
Androgens | 3 | 2023 | 173 | 0.460 |
Why?
|
Robotic Surgical Procedures | 3 | 2023 | 287 | 0.450 |
Why?
|
Health Services Accessibility | 5 | 2020 | 414 | 0.440 |
Why?
|
Peripheral Nerves | 1 | 2013 | 36 | 0.440 |
Why?
|
Surveys and Questionnaires | 6 | 2024 | 2582 | 0.430 |
Why?
|
Patient Reported Outcome Measures | 3 | 2023 | 189 | 0.430 |
Why?
|
Physician-Patient Relations | 2 | 2015 | 618 | 0.430 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 1349 | 0.430 |
Why?
|
Quality Improvement | 5 | 2022 | 440 | 0.420 |
Why?
|
Multivariate Analysis | 6 | 2018 | 995 | 0.420 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 171 | 0.420 |
Why?
|
Automation | 1 | 2012 | 111 | 0.410 |
Why?
|
Communication | 1 | 2015 | 452 | 0.410 |
Why?
|
Taxoids | 2 | 2023 | 130 | 0.400 |
Why?
|
Kaplan-Meier Estimate | 4 | 2024 | 861 | 0.400 |
Why?
|
Cost Savings | 4 | 2019 | 69 | 0.390 |
Why?
|
Biomarkers, Tumor | 1 | 2019 | 1519 | 0.390 |
Why?
|
Carcinoma in Situ | 1 | 2011 | 54 | 0.390 |
Why?
|
Urinary Incontinence | 4 | 2023 | 213 | 0.370 |
Why?
|
Urogenital Neoplasms | 2 | 2020 | 25 | 0.370 |
Why?
|
Lymph Node Excision | 2 | 2010 | 220 | 0.360 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2017 | 564 | 0.360 |
Why?
|
Guideline Adherence | 5 | 2021 | 226 | 0.360 |
Why?
|
Adenocarcinoma | 2 | 2018 | 1183 | 0.360 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 2402 | 0.350 |
Why?
|
Recovery of Function | 4 | 2023 | 289 | 0.340 |
Why?
|
BCG Vaccine | 1 | 2009 | 33 | 0.340 |
Why?
|
Surgery, Computer-Assisted | 1 | 2010 | 98 | 0.340 |
Why?
|
Health Services Needs and Demand | 3 | 2020 | 103 | 0.330 |
Why?
|
Urologic Surgical Procedures | 1 | 2010 | 147 | 0.330 |
Why?
|
Adult | 17 | 2024 | 26230 | 0.320 |
Why?
|
Drug Industry | 3 | 2023 | 54 | 0.320 |
Why?
|
Disease-Free Survival | 4 | 2023 | 1212 | 0.320 |
Why?
|
Retroperitoneal Space | 1 | 2008 | 38 | 0.320 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 2629 | 0.320 |
Why?
|
Health Resources | 2 | 2020 | 81 | 0.320 |
Why?
|
Clinical Decision-Making | 3 | 2019 | 269 | 0.310 |
Why?
|
Risk Factors | 8 | 2019 | 5430 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 2529 | 0.310 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 836 | 0.310 |
Why?
|
Registries | 4 | 2023 | 750 | 0.300 |
Why?
|
Health Care Reform | 3 | 2016 | 86 | 0.300 |
Why?
|
Clinical Protocols | 2 | 2018 | 157 | 0.300 |
Why?
|
Prospective Studies | 8 | 2023 | 4257 | 0.290 |
Why?
|
Health Services | 2 | 2017 | 56 | 0.290 |
Why?
|
Sexual Behavior | 7 | 2022 | 307 | 0.290 |
Why?
|
Testicular Neoplasms | 1 | 2008 | 113 | 0.290 |
Why?
|
Perioperative Care | 2 | 2019 | 166 | 0.290 |
Why?
|
Hematuria | 2 | 2024 | 51 | 0.290 |
Why?
|
Penile Erection | 2 | 2018 | 22 | 0.290 |
Why?
|
Reimbursement Mechanisms | 2 | 2019 | 41 | 0.280 |
Why?
|
Neoplasm Grading | 5 | 2016 | 366 | 0.280 |
Why?
|
Neoadjuvant Therapy | 2 | 2019 | 357 | 0.280 |
Why?
|
Patient Preference | 2 | 2018 | 108 | 0.270 |
Why?
|
Age Factors | 3 | 2019 | 1855 | 0.270 |
Why?
|
Kallikreins | 2 | 2016 | 49 | 0.270 |
Why?
|
Diffusion of Innovation | 4 | 2014 | 71 | 0.260 |
Why?
|
Cystoscopy | 2 | 2024 | 39 | 0.260 |
Why?
|
Remote Consultation | 2 | 2015 | 16 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 318 | 0.260 |
Why?
|
Early Detection of Cancer | 2 | 2020 | 408 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 303 | 0.260 |
Why?
|
Urologic Diseases | 2 | 2015 | 45 | 0.250 |
Why?
|
Biopsy | 4 | 2022 | 1186 | 0.240 |
Why?
|
Urinary Retention | 1 | 2024 | 42 | 0.240 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.240 |
Why?
|
Body Mass Index | 1 | 2007 | 767 | 0.240 |
Why?
|
Incidence | 3 | 2021 | 1587 | 0.230 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2024 | 107 | 0.230 |
Why?
|
Pyrimidinones | 1 | 2023 | 37 | 0.230 |
Why?
|
Cross-Sectional Studies | 5 | 2023 | 1685 | 0.230 |
Why?
|
Certificate of Need | 2 | 2012 | 3 | 0.220 |
Why?
|
Risk Adjustment | 2 | 2019 | 39 | 0.210 |
Why?
|
Sexual Health | 1 | 2022 | 17 | 0.210 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2023 | 524 | 0.210 |
Why?
|
Mass Screening | 3 | 2019 | 631 | 0.200 |
Why?
|
Psychometrics | 2 | 2021 | 328 | 0.200 |
Why?
|
Health Services Misuse | 2 | 2012 | 19 | 0.200 |
Why?
|
Digestive System Surgical Procedures | 1 | 2023 | 124 | 0.200 |
Why?
|
Patient Selection | 3 | 2020 | 686 | 0.200 |
Why?
|
Neoplasm Invasiveness | 4 | 2019 | 574 | 0.200 |
Why?
|
Oncologists | 1 | 2021 | 36 | 0.200 |
Why?
|
Predictive Value of Tests | 3 | 2016 | 1703 | 0.200 |
Why?
|
Databases, Factual | 4 | 2020 | 846 | 0.190 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2019 | 477 | 0.190 |
Why?
|
Laparoscopy | 1 | 2008 | 762 | 0.190 |
Why?
|
Academic Medical Centers | 1 | 2024 | 383 | 0.190 |
Why?
|
Early Termination of Clinical Trials | 1 | 2020 | 16 | 0.190 |
Why?
|
Hospitalization | 2 | 2017 | 868 | 0.190 |
Why?
|
Brachytherapy | 2 | 2015 | 121 | 0.190 |
Why?
|
Data Accuracy | 2 | 2018 | 31 | 0.190 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 857 | 0.190 |
Why?
|
Oncology Service, Hospital | 1 | 2020 | 6 | 0.190 |
Why?
|
Geography | 1 | 2021 | 228 | 0.190 |
Why?
|
Obesity | 1 | 2007 | 968 | 0.190 |
Why?
|
Urination Disorders | 2 | 2011 | 50 | 0.190 |
Why?
|
Pandemics | 3 | 2023 | 760 | 0.180 |
Why?
|
Nephrectomy | 2 | 2016 | 293 | 0.180 |
Why?
|
Patient Care Management | 2 | 2017 | 31 | 0.180 |
Why?
|
Physical Fitness | 1 | 2020 | 51 | 0.180 |
Why?
|
Urinary Catheters | 1 | 2019 | 6 | 0.180 |
Why?
|
Muscle Neoplasms | 1 | 2019 | 18 | 0.180 |
Why?
|
Florida | 1 | 2019 | 56 | 0.170 |
Why?
|
Conservative Treatment | 1 | 2019 | 20 | 0.170 |
Why?
|
Public Health Surveillance | 1 | 2019 | 21 | 0.170 |
Why?
|
Data Interpretation, Statistical | 1 | 2021 | 299 | 0.170 |
Why?
|
Economics, Hospital | 1 | 2019 | 11 | 0.170 |
Why?
|
Reproducibility of Results | 5 | 2021 | 2742 | 0.170 |
Why?
|
Attitude of Health Personnel | 1 | 2024 | 642 | 0.170 |
Why?
|
Postoperative Period | 1 | 2020 | 307 | 0.160 |
Why?
|
Mastectomy | 1 | 2021 | 243 | 0.160 |
Why?
|
Medication Adherence | 1 | 2020 | 134 | 0.160 |
Why?
|
Margins of Excision | 1 | 2018 | 39 | 0.160 |
Why?
|
Subacute Care | 1 | 2018 | 13 | 0.160 |
Why?
|
Urethral Stricture | 1 | 2018 | 14 | 0.160 |
Why?
|
Quality Assurance, Health Care | 1 | 2020 | 224 | 0.160 |
Why?
|
Insurance Benefits | 1 | 2018 | 8 | 0.160 |
Why?
|
Self-Help Devices | 1 | 2018 | 6 | 0.160 |
Why?
|
Health Services Research | 2 | 2016 | 137 | 0.160 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 1710 | 0.160 |
Why?
|
Internet | 2 | 2017 | 317 | 0.160 |
Why?
|
Physician Assistants | 2 | 2024 | 22 | 0.160 |
Why?
|
Hand Disinfection | 1 | 2018 | 17 | 0.160 |
Why?
|
Device Removal | 1 | 2019 | 167 | 0.160 |
Why?
|
Parents | 1 | 2021 | 283 | 0.160 |
Why?
|
Men's Health | 1 | 2017 | 6 | 0.150 |
Why?
|
Practice Management, Medical | 1 | 2017 | 23 | 0.150 |
Why?
|
Teaching Materials | 1 | 2017 | 14 | 0.150 |
Why?
|
Public Sector | 1 | 2017 | 12 | 0.150 |
Why?
|
Urethra | 1 | 2018 | 115 | 0.150 |
Why?
|
Salvage Therapy | 1 | 2018 | 235 | 0.150 |
Why?
|
Academies and Institutes | 1 | 2017 | 31 | 0.150 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2017 | 35 | 0.150 |
Why?
|
Exercise | 2 | 2023 | 321 | 0.140 |
Why?
|
Organ Sparing Treatments | 1 | 2017 | 46 | 0.140 |
Why?
|
Nephrotomy | 1 | 2016 | 1 | 0.140 |
Why?
|
Follow-Up Studies | 4 | 2024 | 3655 | 0.140 |
Why?
|
Preoperative Period | 1 | 2017 | 93 | 0.140 |
Why?
|
Attitude to Health | 3 | 2014 | 221 | 0.140 |
Why?
|
Orthopedic Procedures | 1 | 2018 | 127 | 0.140 |
Why?
|
Hospital Communication Systems | 1 | 2016 | 4 | 0.140 |
Why?
|
Societies, Medical | 1 | 2020 | 561 | 0.140 |
Why?
|
Failure to Thrive | 1 | 2016 | 17 | 0.140 |
Why?
|
Confidence Intervals | 2 | 2016 | 226 | 0.140 |
Why?
|
Bone Density | 1 | 2017 | 209 | 0.140 |
Why?
|
Information Seeking Behavior | 1 | 2016 | 14 | 0.140 |
Why?
|
Patient Care Planning | 1 | 2016 | 82 | 0.140 |
Why?
|
Japan | 1 | 2016 | 303 | 0.140 |
Why?
|
Algorithms | 1 | 2024 | 1857 | 0.130 |
Why?
|
Pilot Projects | 1 | 2018 | 860 | 0.130 |
Why?
|
General Surgery | 1 | 2018 | 235 | 0.130 |
Why?
|
Language | 1 | 2017 | 154 | 0.130 |
Why?
|
Creatinine | 1 | 2016 | 295 | 0.130 |
Why?
|
Fever | 1 | 2016 | 127 | 0.130 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 130 | 0.130 |
Why?
|
Feasibility Studies | 2 | 2020 | 769 | 0.130 |
Why?
|
Carcinoma, Renal Cell | 2 | 2010 | 432 | 0.130 |
Why?
|
Anastomosis, Surgical | 1 | 2016 | 270 | 0.130 |
Why?
|
Glomerular Filtration Rate | 1 | 2016 | 278 | 0.130 |
Why?
|
Denosumab | 1 | 2014 | 2 | 0.130 |
Why?
|
Case-Control Studies | 1 | 2019 | 1846 | 0.120 |
Why?
|
Reproductive Health | 1 | 2015 | 34 | 0.120 |
Why?
|
Coitus | 1 | 2014 | 20 | 0.120 |
Why?
|
Diphosphonates | 1 | 2014 | 36 | 0.120 |
Why?
|
American Cancer Society | 1 | 2014 | 13 | 0.120 |
Why?
|
Glucocorticoids | 1 | 2017 | 359 | 0.120 |
Why?
|
Stress, Psychological | 1 | 2017 | 321 | 0.120 |
Why?
|
Decision Support Systems, Clinical | 1 | 2015 | 105 | 0.120 |
Why?
|
Environment | 1 | 2015 | 224 | 0.120 |
Why?
|
Technology Transfer | 1 | 2013 | 3 | 0.110 |
Why?
|
Stents | 1 | 2016 | 390 | 0.110 |
Why?
|
Analgesics, Opioid | 1 | 2018 | 435 | 0.110 |
Why?
|
Administration, Intravesical | 2 | 2011 | 33 | 0.110 |
Why?
|
Adaptation, Psychological | 3 | 2022 | 162 | 0.110 |
Why?
|
Population Surveillance | 1 | 2014 | 217 | 0.110 |
Why?
|
Tumor Burden | 1 | 2014 | 303 | 0.110 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 1095 | 0.110 |
Why?
|
Health Promotion | 1 | 2014 | 159 | 0.110 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 146 | 0.100 |
Why?
|
Vitamin D | 1 | 2014 | 266 | 0.100 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 412 | 0.100 |
Why?
|
Survival Analysis | 3 | 2021 | 1542 | 0.100 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 53 | 0.100 |
Why?
|
Diet | 1 | 2015 | 442 | 0.100 |
Why?
|
Radiosurgery | 1 | 2015 | 280 | 0.100 |
Why?
|
Radiotherapy, Conformal | 1 | 2012 | 84 | 0.100 |
Why?
|
Neoplasm, Residual | 1 | 2013 | 175 | 0.100 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 429 | 0.100 |
Why?
|
Nurse Practitioners | 1 | 2011 | 31 | 0.100 |
Why?
|
Internship and Residency | 1 | 2020 | 1036 | 0.100 |
Why?
|
Risk Assessment | 3 | 2016 | 2281 | 0.090 |
Why?
|
Delayed Diagnosis | 1 | 2010 | 32 | 0.090 |
Why?
|
Comorbidity | 3 | 2019 | 943 | 0.090 |
Why?
|
Patient Satisfaction | 3 | 2021 | 459 | 0.090 |
Why?
|
Blood Loss, Surgical | 1 | 2010 | 115 | 0.090 |
Why?
|
Adenoma, Oxyphilic | 1 | 2009 | 30 | 0.090 |
Why?
|
Calcium | 1 | 2014 | 1170 | 0.090 |
Why?
|
Organ Size | 1 | 2010 | 367 | 0.090 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2014 | 954 | 0.080 |
Why?
|
Valsalva Maneuver | 1 | 2008 | 6 | 0.080 |
Why?
|
Dissection | 1 | 2008 | 43 | 0.080 |
Why?
|
Insurance Claim Review | 2 | 2019 | 46 | 0.080 |
Why?
|
Cough | 1 | 2008 | 55 | 0.080 |
Why?
|
Young Adult | 2 | 2017 | 6171 | 0.080 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 454 | 0.080 |
Why?
|
Lymphatic Metastasis | 1 | 2009 | 498 | 0.080 |
Why?
|
Monitoring, Intraoperative | 1 | 2008 | 110 | 0.080 |
Why?
|
Colectomy | 2 | 2019 | 168 | 0.080 |
Why?
|
Suburethral Slings | 1 | 2008 | 75 | 0.080 |
Why?
|
Aortic Aneurysm, Abdominal | 2 | 2019 | 119 | 0.070 |
Why?
|
Adolescent | 2 | 2017 | 9125 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2009 | 798 | 0.070 |
Why?
|
Breast Neoplasms | 1 | 2021 | 2972 | 0.070 |
Why?
|
Prosthesis Implantation | 1 | 2008 | 126 | 0.070 |
Why?
|
Treatment Failure | 1 | 2007 | 289 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2011 | 390 | 0.070 |
Why?
|
Decision Making | 2 | 2023 | 658 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2011 | 476 | 0.070 |
Why?
|
Risk | 3 | 2013 | 660 | 0.070 |
Why?
|
Urinary Incontinence, Stress | 1 | 2008 | 196 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 379 | 0.060 |
Why?
|
Family Characteristics | 2 | 2014 | 49 | 0.060 |
Why?
|
Videoconferencing | 1 | 2024 | 15 | 0.060 |
Why?
|
Leuprolide | 1 | 2024 | 35 | 0.060 |
Why?
|
Industry | 1 | 2023 | 17 | 0.060 |
Why?
|
Pyrrolidines | 1 | 2023 | 59 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2018 | 577 | 0.050 |
Why?
|
Medicaid | 2 | 2019 | 225 | 0.050 |
Why?
|
Patient Compliance | 1 | 2023 | 228 | 0.050 |
Why?
|
State Medicine | 1 | 2022 | 12 | 0.050 |
Why?
|
England | 1 | 2022 | 39 | 0.050 |
Why?
|
Europe | 1 | 2023 | 313 | 0.050 |
Why?
|
Personal Satisfaction | 1 | 2021 | 62 | 0.050 |
Why?
|
Group Practice | 1 | 2021 | 7 | 0.050 |
Why?
|
Inpatients | 1 | 2024 | 308 | 0.050 |
Why?
|
Lung Neoplasms | 1 | 2014 | 2325 | 0.050 |
Why?
|
United Kingdom | 1 | 2021 | 161 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2023 | 253 | 0.050 |
Why?
|
Organizational Innovation | 1 | 2020 | 41 | 0.050 |
Why?
|
Data Collection | 1 | 2022 | 374 | 0.050 |
Why?
|
Patient Care Team | 1 | 2023 | 283 | 0.050 |
Why?
|
Communicable Disease Control | 1 | 2020 | 50 | 0.050 |
Why?
|
Accreditation | 1 | 2020 | 61 | 0.050 |
Why?
|
Income | 1 | 2020 | 81 | 0.040 |
Why?
|
Hospitals | 1 | 2023 | 298 | 0.040 |
Why?
|
Drug Costs | 1 | 2020 | 63 | 0.040 |
Why?
|
Workflow | 1 | 2020 | 78 | 0.040 |
Why?
|
Perception | 1 | 2020 | 177 | 0.040 |
Why?
|
Health Personnel | 1 | 2021 | 209 | 0.040 |
Why?
|
Marital Status | 1 | 2019 | 42 | 0.040 |
Why?
|
Bias | 1 | 2019 | 130 | 0.040 |
Why?
|
Mental Health | 1 | 2020 | 173 | 0.040 |
Why?
|
Travel | 1 | 2019 | 71 | 0.040 |
Why?
|
Administration, Oral | 1 | 2020 | 684 | 0.040 |
Why?
|
Urologic Surgical Procedures, Male | 1 | 2018 | 14 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2023 | 508 | 0.040 |
Why?
|
Medical Audit | 1 | 2018 | 39 | 0.040 |
Why?
|
Health Care Surveys | 1 | 2019 | 281 | 0.040 |
Why?
|
Michigan | 1 | 2018 | 53 | 0.040 |
Why?
|
Cause of Death | 1 | 2019 | 270 | 0.040 |
Why?
|
Holistic Health | 1 | 2017 | 9 | 0.040 |
Why?
|
Biopsy, Needle | 1 | 2018 | 235 | 0.040 |
Why?
|
Guidelines as Topic | 1 | 2018 | 159 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2014 | 1837 | 0.040 |
Why?
|
Seminal Vesicles | 1 | 2017 | 39 | 0.040 |
Why?
|
Disease Management | 1 | 2019 | 328 | 0.040 |
Why?
|
Cisplatin | 1 | 2019 | 615 | 0.040 |
Why?
|
Models, Statistical | 1 | 2020 | 575 | 0.040 |
Why?
|
Education, Medical, Graduate | 1 | 2020 | 384 | 0.030 |
Why?
|
Program Evaluation | 1 | 2018 | 302 | 0.030 |
Why?
|
Medical Overuse | 1 | 2016 | 36 | 0.030 |
Why?
|
Self Efficacy | 1 | 2016 | 54 | 0.030 |
Why?
|
Sex Factors | 1 | 2019 | 1060 | 0.030 |
Why?
|
Los Angeles | 1 | 2015 | 28 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2018 | 203 | 0.030 |
Why?
|
Orgasm | 1 | 2014 | 9 | 0.030 |
Why?
|
Intestinal Diseases | 1 | 2015 | 79 | 0.030 |
Why?
|
Clinical Competence | 1 | 2020 | 779 | 0.030 |
Why?
|
Social Support | 1 | 2016 | 204 | 0.030 |
Why?
|
Life Style | 1 | 2015 | 172 | 0.030 |
Why?
|
Urban Population | 1 | 2015 | 223 | 0.030 |
Why?
|
Self Report | 1 | 2015 | 294 | 0.030 |
Why?
|
Managed Care Programs | 1 | 2012 | 42 | 0.030 |
Why?
|
Diagnostic Tests, Routine | 1 | 2013 | 62 | 0.030 |
Why?
|
State Government | 1 | 2012 | 22 | 0.030 |
Why?
|
Mortality | 1 | 2013 | 150 | 0.030 |
Why?
|
Child | 1 | 2023 | 7074 | 0.030 |
Why?
|
Disease Progression | 1 | 2016 | 1488 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2010 | 66 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2011 | 180 | 0.020 |
Why?
|
Necrosis | 1 | 2010 | 210 | 0.020 |
Why?
|
Urodynamics | 1 | 2008 | 122 | 0.020 |
Why?
|